"Insulin degludec may provide dosing options for patients who, because of their lifestyle, require some flexibility in adhering to an insulin regimen, and it may also reduce the risk of hypoglycemia compared with the basal insulins that are currently available." | ( Insulin degludec--a new-generation basal insulin. Atkin, SL; Wakil, A, 2012) | 3.26 |
" Once-daily dosing produces a steady-state profile characterized by a near-constant effect, which varies little from injection to injection in a given patient." | ( Insulin degludec: overview of a novel ultra long-acting basal insulin. Davies, M; Gough, SC; Harris, S; Woo, V, 2013) | 1.83 |
" Participants were randomized to 1) once-daily (OD) IDeg in a prespecified dosing schedule, creating 8-40-h intervals between injections (IDeg OD Flex; n = 229); 2) once-daily IDeg at the main evening meal (IDeg OD; n = 228); or 3) once-daily insulin glargine at the same time each day (IGlar OD; n = 230)." | ( The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individ Atkin, SL; Bain, S; Begtrup, K; Birkeland, KI; Blonde, L; Gough, SC; Johansen, T; Meneghini, L; Raz, I; Shestakova, M, 2013) | 0.69 |
"The use of extreme dosing intervals of 8-40 h demonstrates that the daily injection time of IDeg can be varied without compromising glycemic control or safety." | ( The efficacy and safety of insulin degludec given in variable once-daily dosing intervals compared with insulin glargine and insulin degludec dosed at the same time daily: a 26-week, randomized, open-label, parallel-group, treat-to-target trial in individ Atkin, SL; Bain, S; Begtrup, K; Birkeland, KI; Blonde, L; Gough, SC; Johansen, T; Meneghini, L; Raz, I; Shestakova, M, 2013) | 0.69 |
" Because of its peakless, extended and highly predictable glucose-lowering effect, once-daily dosing on a flexible schedule may be feasible with degludec." | ( Flexibly timed once-daily dosing with degludec: a new ultra-long-acting basal insulin. Josse, RG; Woo, V, 2013) | 0.39 |
" In addition, trials examining a flexible dosing regimen of insulin degludec in patients with type 1 or 2 diabetes show the potential for adjusting the injection time, without compromising glycaemic control or safety." | ( Insulin degludec and insulin degludec/insulin aspart: a review of their use in the management of diabetes mellitus. Keating, GM, 2013) | 2.07 |
"The concentration-time profiles of IDeg U100 and IDeg U200 were similar, and a post-hoc analysis showed bioequivalence between these formulations, as the 90 % confidence intervals (CIs) of the U200/U100 ratios for area under the steady-state serum IDeg concentration-time curve during a dosing interval (τ; 0-24 h) (AUCτ,SS,IDeg) (0." | ( A comparison of the steady-state pharmacokinetic and pharmacodynamic profiles of 100 and 200 U/mL formulations of ultra-long-acting insulin degludec. Adrian, CL; Deller, S; Haahr, H; Koehler, G; Korsatko, S; Mader, JK; Neubauer, K; Pieber, TR; Thomsen, H, 2013) | 0.59 |
"Insulin degludec (IDeg) is a new basal insulin in development with a flat, ultra-long action profile that may permit dosing using a simplified titration algorithm with less frequent self-measured blood glucose (SMBG) measurements and more simplified titration steps than currently available basal insulins." | ( Insulin degludec once-daily in type 2 diabetes: simple or step-wise titration (BEGIN: once simple use). Brod, M; Niemeyer, M; Ocampo Francisco, AM; Philis-Tsimikas, A; Rothman, J, 2013) | 3.28 |
" A number of new, long-acting basal insulins are in development that provide good metabolic control, but with a lower risk of hypoglycaemia than currently available insulins, and greater flexibility in dosing time from day to day." | ( Insulin degludec--the impact of a new basal insulin on care in type 2 diabetes. Cos, X; Khunti, K; Rutten, G, 2014) | 1.85 |
" Pharmacokinetic endpoints included the total exposure of IDeg, ie the area under the IDeg serum concentration curve during one dosing interval at steady state (AUC(IDeg,τ,SS)) (τ = 0-24 h, equal to one dosing interval) and the maximum IDeg serum concentration at steady state (C(max,IDeg,SS))." | ( Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus. Deller, S; Glettler, K; Haahr, H; Hastrup, H; Koehler, G; Korsatko, S; Mader, JK; Pieber, TR; Søndergaard, F; Treiber, G; Urschitz, M; Wolf, M, 2014) | 0.67 |
" Mean AUC(IDeg,0-12h,SS)/AUC(IDeg,τ,SS) was 53 % in both younger adult and elderly subjects, showing that in both age groups IDeg exposure was evenly distributed across the first and second 12 h of the 24-hour dosing interval." | ( Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus. Deller, S; Glettler, K; Haahr, H; Hastrup, H; Koehler, G; Korsatko, S; Mader, JK; Pieber, TR; Søndergaard, F; Treiber, G; Urschitz, M; Wolf, M, 2014) | 0.67 |
"The exposure of IDeg at steady state during once-daily dosing was similar in younger adult and elderly subjects." | ( Ultra-long pharmacokinetic properties of insulin degludec are comparable in elderly subjects and younger adults with type 1 diabetes mellitus. Deller, S; Glettler, K; Haahr, H; Hastrup, H; Koehler, G; Korsatko, S; Mader, JK; Pieber, TR; Søndergaard, F; Treiber, G; Urschitz, M; Wolf, M, 2014) | 0.67 |
" Simulated steady-state insulin degludec pharmacokinetic profiles showed an even distribution of exposure across a 24-h dosing interval regardless of hepatic function status." | ( Insulin degludec: pharmacokinetic properties in subjects with hepatic impairment. Arold, G; Haahr, H; Højbjerre, M; Klim, S; Kupčová, V; Roepstorff, C, 2014) | 2.15 |
"4 U/kg IDeg or insulin glargine (IGlar), respectively, on two separate dosing visits, with pharmacokinetic blood sampling up to 72-h postdose." | ( Insulin degludec's ultra-long pharmacokinetic properties observed in adults are retained in children and adolescents with type 1 diabetes. Aschemeier, B; Biester, T; Blaesig, S; Danne, T; Granhall, C; Haahr, H; Kordonouri, O; Kristensen, NR; Remus, K; Søndergaard, F, 2014) | 1.85 |
" Patients were allocated randomly to a sequence of 2 treatment periods, separated by a 7- to 21-day washout period, with once-daily IDeg or insulin detemir dosing for 6 days at a predefined fixed dose level (0." | ( Pharmacokinetic and pharmacodynamic responses of insulin degludec in African American, white, and Hispanic/Latino patients with type 2 diabetes mellitus. Haahr, H; Hompesch, M; Morrow, L; Roepstorff, C; Thomsen, HF; Watkins, E, 2014) | 0.66 |
"The inferior glycaemic control and increased risk of hypoglycaemia with IDeg 3TW compared with IGlar OD do not support a three-times-weekly dosing regimen." | ( Efficacy and safety of insulin degludec three times a week versus insulin glargine once a day in insulin-naive patients with type 2 diabetes: results of two phase 3, 26 week, randomised, open-label, treat-to-target, non-inferiority trials. Bode, B; DeVries, JH; Johansen, T; Leiter, LA; Moses, A; Ratner, R; Russell-Jones, D; Zinman, B, 2013) | 0.7 |
" In addition, when dosing intervals vary substantially from day to day, degludec continues to be effective and to maintain a low rate of nocturnal hypoglycemia." | ( Insulin degludec, a long-acting once-daily basal analogue for type 1 and type 2 diabetes mellitus. Berard, L; MacNeill, G, 2015) | 1.86 |
" The pharmacokinetic profile of IDeg demonstrates an even distribution of exposure across one dosing interval." | ( A review of the pharmacological properties of insulin degludec and their clinical relevance. Haahr, H; Heise, T, 2014) | 0.66 |
" Clinical trials have shown that this ultra long-acting insulin analogue administered in a flexible dosage treatment, reached a good glycaemic control with no increase on hypoglycemia risk." | ( [Therapeutic compliance and flexibility in the use of basal insulins]. Costa Gil, JE; Faingold, MC; Fuente, GV; Litwak, LE, 2014) | 0.4 |
" In once-daily dosing regimen it reaches steady state after approximately 3 days." | ( Translating structure to clinical properties of an ideal basal insulin. Bantwal, G; Sahay, RK; Unnikrishnan, AG, 2014) | 0.4 |
" In addition, trials examining a flexible dosing regimen of insulin degludec in patients with type 1 or 2 diabetes show the potential for adjusting the injection time, without compromising glycaemic control or safety." | ( Treating to target in type 2 diabetes: the BEGIN trial programme. Chowdhury, S; Rao, PV; Wangnoo, SK, 2014) | 0.64 |
" oral therapy and also the flexible dosing options." | ( Efficacy without barriers to insulin therapy: lessons from the BEGIN trial programme. Jain, SM; Kumar, A; Kumar, H; Mithal, A, 2014) | 0.4 |
" It is potentially dangerous and the fear of hypoglycaemia may lead to sub-optimal dosing and inadequate glycaemic control." | ( Understanding the safety of the new ultra long acting basal insulin. Gupta, V; Kalra, S; Kesavadev, J; Ramachandran, A, 2014) | 0.4 |
"This may enable for a more flexible daytime dosing versus up to now available basal insulins." | ( [Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes]. Jaeckel, E; Lüdemann, J; Milek, K; Segner, A; Wilhelm, B, 2014) | 0.68 |
" Both phase 3 studies compared a daytime flexible dosing of IDeg (IDeg-flex) with IDeg at the evening meal (IDeg-evening) and IDler at a fixed daytime." | ( [Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes]. Jaeckel, E; Lüdemann, J; Milek, K; Segner, A; Wilhelm, B, 2014) | 0.68 |
"This may enable for a more flexible daytime dosing versus up to now available basal insulins." | ( [Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes]. Jaeckel, E; Lüdemann, J; Milek, K; Segner, A; Wilhelm, B, 2014) | 0.68 |
" Both phase 3 studies compared a daytime flexible dosing of IDeg (IDeg-flex) with IDeg at the evening meal (IDeg-evening) and IDler at a fixed daytime." | ( [Daytime flexible application of Insulin degludec in patients with type 1 diabetes or type 2 diabetes]. Jaeckel, E; Lüdemann, J; Milek, K; Segner, A; Wilhelm, B, 2014) | 0.68 |
" The recent approval of insulin degludec/liraglutide administered in a fixed ratio combination is unique not simply for the additive benefits of the two agents, but because it now permits adjustable dosing of liraglutide together with insulin, providing better glucose control than with either agent alone at lower dose levels." | ( First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes. Rendell, M, 2015) | 1.01 |
"The limitations of current basal insulin preparations include concerns related to their pharmacokinetic and pharmacodynamic properties, hypoglycaemia, weight gain, and perception of management complexity, including rigid dosing schedules." | ( Clinical use of insulin degludec. Cariou, B; Evans, M; Gross, JL; Harris, S; Landstedt-Hallin, L; Meneghini, L; Mithal, A; Rodriguez, MR; Vora, J, 2015) | 0.76 |
" Liraglutide exposure was lower when dosed as IDegLira but met the criterion for equivalence." | ( Preserved pharmacokinetic exposure and distinct glycemic effects of insulin degludec and liraglutide in IDegLira, a fixed-ratio combination therapy. Bode, B; Ingwersen, SH; Jacobsen, LV; Kapitza, C; Poulsen, P, 2015) | 0.65 |
" The evenly distributed glucose-lowering effect of IDeg was confirmed by the AUCGIR across one dosing interval, as each of the four 6-h intervals across one dosing interval contributed ∼ 25% of the AUCGIR,τ,SS." | ( Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Bøttcher, SG; Haahr, H; Heise, T; Hermanski, L; Hövelmann, U; Nosek, L, 2015) | 0.65 |
" Exposure and glucose-lowering effects are more stable and evenly distributed across one dosing interval for IDeg versus IGlar (Clinical trials." | ( Comparison of the pharmacokinetic and pharmacodynamic profiles of insulin degludec and insulin glargine. Bøttcher, SG; Haahr, H; Heise, T; Hermanski, L; Hövelmann, U; Nosek, L, 2015) | 0.65 |
"8 mg in combination with metformin (≥1500 mg) were randomized to addition of once-daily IDeg ('IDeg add-on to liraglutide' arm; n = 174) or placebo ('placebo add-on to liraglutide' arm; n = 172), with dosing of both IDeg and placebo based on titration guidelines." | ( Effect of adding insulin degludec to treatment in patients with type 2 diabetes inadequately controlled with metformin and liraglutide: a double-blind randomized controlled trial (BEGIN: ADD TO GLP-1 Study). Andersen, TH; Aroda, VR; Bailey, TS; Cariou, B; Kumar, S; Leiter, LA; Philis-Tsimikas, A; Raskin, P; Zacho, J, 2016) | 0.77 |
" At steady state, total glucose-lowering effect (area under the glucose infusion rate [GIR] curve during one dosing interval [τ, 0-24 h] at steady state [AUCGIR ,τ, SS]) was 1,446 mg/kg and total exposure (geometric mean) of IDeg (AUCID eg,τ, SS) was 81,270 pmol h/L." | ( Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients. Bardtrum, L; Haahr, H; Hirao, K; Ikushima, I; Kaku, K, 2016) | 0.69 |
" These data support once-daily dosing of IDeg in all patients." | ( Pharmacokinetic and pharmacodynamic properties of insulin degludec in Japanese patients with type 1 diabetes mellitus reflect similarities with Caucasian patients. Bardtrum, L; Haahr, H; Hirao, K; Ikushima, I; Kaku, K, 2016) | 0.69 |
" The characteristics of the GIR profile for IDegAsp were retained when simulated to steady state in a twice-daily dosing regimen." | ( Insulin degludec/insulin aspart in Japanese patients with type 1 diabetes mellitus: Distinct prandial and basal glucose-lowering effects. Bardtrum, L; Haahr, H; Ikushima, I; Sasaki, T, 2016) | 1.88 |
"This was a 26-week, multicenter, open-label, randomized, treat-to-target trial, with a 2 × 2 factorial design comparing IDeg flexible (allowing dosing ±8 h from an agreed dosing time) with IDeg fixed dosing (at the same time each day)." | ( Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26-week, treat-to-target trial. Hersløv, ML; Hyllested-Winge, J; Jinnouchi, H; Kadowaki, T; Kaku, K; Nakamura, S, 2016) | 0.71 |
"The majority of doses were taken within 2 h of the agreed dosing time, showing a high level of adherence among Japanese patients." | ( Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26-week, treat-to-target trial. Hersløv, ML; Hyllested-Winge, J; Jinnouchi, H; Kadowaki, T; Kaku, K; Nakamura, S, 2016) | 0.71 |
"These results showed the efficacy and safety of allowing patients to vary the time they dosed IDeg, when necessary, in Japanese patients with type 2 diabetes." | ( Efficacy and safety of once-daily insulin degludec dosed flexibly at convenient times vs fixed dosing at the same time each day in a Japanese cohort with type 2 diabetes: A randomized, 26-week, treat-to-target trial. Hersløv, ML; Hyllested-Winge, J; Jinnouchi, H; Kadowaki, T; Kaku, K; Nakamura, S, 2016) | 0.71 |
"In people with T2DM, once- and twice-daily dosing provides similar overall glycaemic control (HbA1c ) to current modern insulins, but with lower risk of nocturnal hypoglycaemia." | ( Clinical use of the co-formulation of insulin degludec and insulin aspart. Arechavaleta, R; Awata, T; Bain, SC; Ceriello, A; Christiansen, JS; Fulcher, GR; Gonzalez-Gálvez, G; Hirose, T; Home, PD; Kaku, K; Kumar, A; Litwak, L; Madsbad, S; Mehta, R; Mithal, A; Pinget, M; Tambascia, M; Tibaldi, J; Unnikrishnan, AG, 2016) | 0.71 |
" Indeed, NPH insulin remains widely used today despite a frequent need for a twice-daily dosing and a relatively high incidence of hypoglycaemia." | ( Impact of the mode of protraction of basal insulin therapies on their pharmacokinetic and pharmacodynamic properties and resulting clinical outcomes. Heise, T; Mathieu, C, 2017) | 0.46 |
" The glucose-lowering effect profile of IDegAsp during once-daily dosing at steady state shows distinct and clearly separated action from the prandial and basal components of IDegAsp." | ( A Review of Insulin Degludec/Insulin Aspart: Pharmacokinetic and Pharmacodynamic Properties and Their Implications in Clinical Use. Fita, EG; Haahr, H; Heise, T, 2017) | 0.83 |
" The day-to-day variability in glucose-lowering effect assessed in 2-hour intervals was consistently low with IDeg over 24 hours, but steadily increased with IGlar-U300 to a maximum at 10 to 12 hours and 12 to 14 hours after dosing (variance ratios 12." | ( Insulin degludec: Lower day-to-day and within-day variability in pharmacodynamic response compared with insulin glargine 300 U/mL in type 1 diabetes. Famulla, S; Haahr, HL; Heise, T; Kaplan, K; Nosek, L; Nørskov, M, 2017) | 1.9 |
" Despite glycated haemoglobin concentrations being lower with IDegLira at end of treatment, confirmed and nocturnal-confirmed hypoglycaemia rates were lower for IDegLira vs IDeg and IGlar U100, irrespective of dosing time." | ( Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used. Chen, R; Heller, S; Jaeckel, E; Jarlov, H; Lehmann, L; Lingvay, I; Norwood, P, 2017) | 0.7 |
"Treatment with IDegLira, vs IDeg and IGlar U100, resulted in lower rates of hypoglycaemia regardless of dosing time and definition of hypoglycaemia used." | ( Rates of hypoglycaemia are lower in patients treated with insulin degludec/liraglutide (IDegLira) than with IDeg or insulin glargine, regardless of the hypoglycaemia definition used. Chen, R; Heller, S; Jaeckel, E; Jarlov, H; Lehmann, L; Lingvay, I; Norwood, P, 2017) | 0.7 |
"Patients were randomized 1:1 to receive once-daily insulin degludec followed by insulin glargine U100 (n = 249) or to receive insulin glargine U100 followed by insulin degludec (n = 252) and randomized 1:1 to morning or evening dosing within each treatment sequence." | ( Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 1 Diabetes: The SWITCH 1 Randomized Clinical Trial. Bailey, TS; Gerety, G; Gumprecht, J; Hansen, CT; Lane, W; Nielsen, TSS; Philis-Tsimikas, A; Warren, M, 2017) | 1.11 |
"Patients were randomized 1:1 to receive once-daily insulin degludec followed by insulin glargine U100 (n = 361) or to receive insulin glargine U100 followed by insulin degludec (n = 360) and randomized 1:1 to morning or evening dosing within each treatment sequence." | ( Effect of Insulin Degludec vs Insulin Glargine U100 on Hypoglycemia in Patients With Type 2 Diabetes: The SWITCH 2 Randomized Clinical Trial. Bhargava, A; Chaykin, L; de la Rosa, R; Handelsman, Y; Kvist, K; Norwood, P; Troelsen, LN; Wysham, C, 2017) | 1.11 |
"38) was similar for both dosing schemes." | ( Reduction in insulin degludec dosing for multiple exercise sessions improves time spent in euglycaemia in people with type 1 diabetes: A randomized crossover trial. Aberer, F; Birnbaumer, P; Bracken, RM; Dietz, P; Eckstein, ML; Hofmann, P; Holler, P; Koehler, G; Kojzar, H; Moser, O; Mueller, A; Pferschy, P; Simi, H; Sourij, C; Sourij, H, 2019) | 0.88 |
"0001), and more even dosing over each 6-h quartile, with insulin degludec 200 U/mL versus insulin glargine 300 U/mL (0." | ( Clinical relevance of pharmacokinetic and pharmacodynamic profiles of insulin degludec (100, 200 U/mL) and insulin glargine (100, 300 U/mL) - a review of evidence and clinical interpretation. Bolli, GB; Fanelli, CG; Owens, DR; S Bailey, T; Yale, JF, 2019) | 0.99 |
"The stable, ultra-long duration of action of insulin degludec (degludec) minimizes fluctuations in glucose-lowering activity over the daily (24-h) dosing period, and comparative studies with other basal insulins suggest that these properties translate into a lower risk of hypoglycemia at equivalent levels of glycemic control." | ( Switching "Real-World" Diabetes Patients to Degludec from Other Basal Insulins Provides Different Clinical Benefits According to Their Baseline Glycemic Control. Haldrup, S; Knudsen, ST; Lapolla, A; Schultes, B; Tentolouris, N; Wolden, ML, 2019) | 0.77 |
" Multiple randomized control trials and real-world evidence studies have demonstrated that the newer second-generation basal insulin analogs, insulin glargine 300 units/mL and insulin degludec 100 or 200 units/mL, provide stable glycemic control with once-daily dosing and are associated with a reduced risk of hypoglycemia compared with previous-generation basal insulin analogs insulin glargine 100 units/mL and insulin detemir." | ( Differentiating Basal Insulin Preparations: Understanding How They Work Explains Why They Are Different. Cheng, AYY; Patel, DK; Reid, TS; Wyne, K, 2019) | 0.71 |
" At 12 months, HbA1c, fasting plasma glucose (FPG), and basal insulin dosage decreased significantly." | ( Switching to Degludec From Other Basal Insulins Is Associated With Reduced Hypoglycemia Rates: A Prospective Study. de Valk, HW; Fadini, GP; Feher, M; Hansen, TK; Jendle, J; Koefoed, MM; Wolden, M; Zimmermann, E, 2019) | 0.51 |
" We present results from 4 nonclinical rat studies evaluating effects of repeated dosing with insulin detemir (≤26 weeks) or degludec (52 weeks) in mammary glands." | ( Evaluation of Cell Proliferation in Rat Mammary Glands Is Not Predictive of the Carcinogenic Potential of Insulin In Vivo. Brinck, PR; Jensen, VFH; Mølck, AM; Nowak, J; Sjögren, I; Thorup, I, ) | 0.13 |
"Patients with inadequate glycemic control or who find their basal insulin dosing inconvenient may benefit from switching to Ideg, with the potential for small improvementa in A1C at lower basal insulin doses." | ( Clinical Utility of Switching to Insulin Degludec From Other Basal Insulins in Adult Patients With Type 1 or Type 2 Diabetes. Bakal, JA; Baran, O; Dersch-Mills, D; Hnatiuk, M; Huyghebaert, T; Roedler, RL, 2022) | 1 |
"Once-weekly insulin icodec could provide a simpler dosing alternative to daily basal insulin in people with type 2 diabetes." | ( Once-Weekly Insulin Icodec vs Once-Daily Insulin Degludec in Adults With Insulin-Naive Type 2 Diabetes: The ONWARDS 3 Randomized Clinical Trial. Asong, M; Desouza, C; Gourdy, P; Kar, S; Lingvay, I; Mu, Y; Vianna, A; Vilsbøll, T; Vinther, S, 2023) | 1.18 |